Alan Ezekowitz's most recent trade in Fulcrum Therapeutics Inc was a trade of 36,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 36,000 | 36,000 | - | - | Stock Option (right to buy) | |
| Septerna Inc. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 16,623 | 16,623 | - | - | Stock Option (Right to Buy) | |
| Organon & Co. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 23,904 | 62,702 | - | - | Phantom Stock | |
| Septerna Inc. | Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.93 per share. | 07 Mar 2025 | 13,319 | 117,420 | - | 6.9 | 92,270 | Common Stock |
| Septerna Inc. | Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.00 per share. | 04 Mar 2025 | 41,355 | 104,101 | - | 6 | 248,130 | Common Stock |
| Septerna Inc. | Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 5.82 per share. | 04 Mar 2025 | 37,835 | 62,746 | - | 5.8 | 220,260 | Common Stock |
| Septerna Inc. | Alan Ezekowitz | Director | Purchase of securities on an exchange or from another person at price $ 6.35 per share. | 04 Mar 2025 | 7,491 | 24,911 | - | 6.3 | 47,544 | Common Stock |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 9,638 | 36,454 | - | - | Phantom Stock | |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 10,086 | 25,285 | - | - | Phantom Stock | |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2022 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Other type of transaction at price $ 0.00 per share. | 27 Jun 2022 | 500 | 14,500 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 5,640 | 14,638 | - | - | Phantom Stock | |
| Fulcrum Therapeutics Inc | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Organon & Co. | Alan Ezekowitz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 8,772 | 8,772 | - | - | Phantom Stock |